BioLife Solutions (NASDAQ:BLFS) Price Target Raised to $31.00 at Northland Securities

BioLife Solutions (NASDAQ:BLFS) had its price target hoisted by Northland Securities from $28.00 to $31.00 in a research report released on Wednesday,Benzinga reports. Northland Securities currently has an outperform rating on the medical equipment provider’s stock.

Other equities analysts have also issued research reports about the company. HC Wainwright dropped their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Craig Hallum lifted their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. KeyCorp increased their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Benchmark restated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, TD Cowen upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Trading Up 2.1 %

NASDAQ BLFS opened at $27.69 on Wednesday. The firm’s fifty day moving average price is $25.91 and its 200 day moving average price is $24.27. BioLife Solutions has a 12 month low of $14.50 and a 12 month high of $28.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -26.12 and a beta of 1.92.

Insider Transactions at BioLife Solutions

In related news, CFO Troy Wichterman sold 987 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the transaction, the chief financial officer now directly owns 121,779 shares of the company’s stock, valued at $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Aby J. Mathew sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total transaction of $232,800.00. Following the completion of the sale, the executive vice president now owns 317,716 shares of the company’s stock, valued at approximately $7,396,428.48. The trade was a 3.05 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 113,129 shares of company stock worth $2,576,818 over the last 90 days. 2.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Mark Sheptoff Financial Planning LLC acquired a new position in shares of BioLife Solutions during the 3rd quarter worth $28,000. Quest Partners LLC purchased a new stake in BioLife Solutions during the third quarter worth about $57,000. GAMMA Investing LLC grew its position in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 748 shares during the period. Canada Pension Plan Investment Board purchased a new position in BioLife Solutions in the second quarter valued at about $122,000. Finally, Arizona State Retirement System acquired a new stake in shares of BioLife Solutions during the 2nd quarter valued at approximately $217,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.